Baxter Investors Face Dec. 15 Deadline as Novum LVP Securities Suits Press Forward

Overview

• The Law Offices of Frank R. Cruz on November 18 invited Baxter shareholders with losses to move for lead-plaintiff appointment by December 15, 2025.
• Lowey Dannenberg and Levi & Korsinsky issued November 17 notices tied to a class period spanning February 23, 2022 through July 30, 2025.
• The complaints allege Baxter’s Novum LVP infusion pump had systemic defects causing underinfusion, overinfusion, and complete non-delivery that posed risks of serious injury or death.
• Filings assert Baxter was notified of multiple malfunctions, injuries, and deaths and that customer alerts were inadequate while design flaws persisted.
• Plaintiffs claim Baxter made materially misleading statements about the device’s safety, rollout, customer feedback, and sales prospects, and investors seek recovery of losses.